The Technical Analyst
Ortho Clinical [OCDX]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Ortho Clinical Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.92% $17.63
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-08-05 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -42.28 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.26x |
| Company: PE -42.28 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 17.12 - 18.14 ( +/- 2.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-27 | Perez David Brian | Sell | 8 576 | Ordinary Shares, $0.00001 par value |
| 2022-05-27 | Hull Carl | Sell | 41 172 | Ordinary Shares, $0.00001 par value |
| 2022-05-27 | Dilsaver Evelyn S | Sell | 5 200 | Ordinary Shares, $0.00001 par value |
| 2022-05-27 | Carlyle Partners Vi Cayman Holdings, L.p. | Sell | 118 106 000 | Ordinary Shares, $0.00001 par value |
| 2022-05-27 | Carlyle Group Inc. | Sell | 118 106 000 | Ordinary Shares, $0.00001 par value |
| INSIDER POWER |
|---|
| -100.00 |
| Last 11 transactions |
| Buy: 10 400 | Sell: 261 566 948 |
Forecast:
01:40 - $17.66
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $17.63 (0.92% ) |
| Volume | 0.789 mill |
| Avg. Vol. | 1.007 mill |
| % of Avg. Vol | 78.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OCDX
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2022-03-10 17:23:00 - Press Release
Ortho Clinical Investor Alert - Kuznicki Law Pllc Investigates Adequacy Of Price And Process In Proposed Sale Of Ortho Clinical Diagnostics Holdings Plc - Ocdx
Cedarhurst, n.y.--(business wire)--kuznicki law pllc is investigating the proposed sale of ortho clinical diagnostics holdings plc (nasdaqgs: ocdx) to quidel corporation (nasdaqgs: qdel). under the terms of the proposed transaction, shareholders of ortho will receive only $7.14 in cash and 0.1055 shares of common stock in the combined company for each share of ortho that they own. kuznicki law is seeking to determine whether this consideration and the process that led to it are adequate, or whe
2021-12-23 07:00:00 - Press Release
Quidel Corporation Signs Definitive Agreement To Acquire Ortho Clinical Diagnostics
San diego & raritan, n.j.--(business wire)--quidel corporation (nasdaq: qdel) (“quidel”) and ortho clinical diagnostics holdings plc (nasdaq: ocdx) (“ortho”) today announced that they have entered into a definitive agreement in which quidel will acquire ortho, one of the world's largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over ortho's closing price on december
2021-10-12 16:15:00 - Press Release
Ortho Clinical Diagnostics To Report Third Quarter 2021 Results On November 3, 2021
Raritan, n.j., oct. 12, 2021 (globe newswire) -- ortho clinical diagnostics holdings plc (nasdaq: ocdx), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended october 3, 2021, after the market close on wednesday, november 3, 2021.
2021-09-14 16:15:00 - Press Release
Ortho Clinical Diagnostics Announces Closing Of Secondary Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Ordinary Shares
Raritan, n.j., sept. 14, 2021 (globe newswire) -- ortho clinical diagnostics holdings plc (nasdaq: ocdx) (the “company”), one of the world's largest pure-play in vitro diagnostics companies, today announced the closing (the “closing”) of the previously announced underwritten secondary offering of 25,300,000 of the company's ordinary shares held by a selling shareholder affiliated with the carlyle group (the “selling shareholder”), which includes the full exercise by the underwriters of their option to purchase up to 3,300,000 additional ordinary shares, at a price of $17.50 per share. as a result of the closing, the company is no longer a “controlled company” within the meaning of the rules of the nasdaq global select market.
2021-09-09 19:15:00 - Press Release
Ortho Clinical Diagnostics Announces Pricing Of Secondary Offering Of Ordinary Shares
Raritan, n.j., sept. 09, 2021 (globe newswire) -- ortho clinical diagnostics holdings plc (nasdaq: ocdx) (the “company”), one of the world's largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the company's ordinary shares held by a selling shareholder affiliated with the carlyle group (the “selling shareholder”) at a price of $17.50 per ordinary share. the offering is expected to close on september 14, 2021, subject to customary closing conditions. the selling shareholder granted the underwriters a 30-day option to purchase up to 3,300,000 additional ordinary shares of the company at the public offering price less the underwriting discount.
Latest News
2022-05-07 18:23:05 - Seeking Alpha
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Chris Smith on Q1 2022 Results - Earnings Call Transcript
Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Chris Smith - Chairman and Chief Executive Officer Joseph Busky - Chief Financial Officer Operator Welcome to the Ortho Clinical Diagnostics First Quarter 2022 Earnings Conference Call and Webcast. At this time, all participants lines are in a listen-only mode.
2022-04-28 13:32:18 - Zacks Investment Research
Why Ortho Clinical (OCDX) Could Beat Earnings Estimates Again
Ortho Clinical (OCDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2022-04-01 13:23:31 - Zacks Investment Research
OCDX vs. DOCS: Which Stock Is the Better Value Option?
2022-03-24 13:33:10 - Zacks Investment Research
Ortho Clinical (OCDX) Upgraded to Strong Buy: Here's What You Should Know
Ortho Clinical (OCDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2022-03-24 09:47:10 - Zacks Investment Research
New Strong Buy Stocks for March 24th
ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.
2022-03-15 12:48:09 - Zacks Investment Research
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?
2022-02-25 13:50:14 - Zacks Investment Research
Will Ortho Clinical (OCDX) Gain on Rising Earnings Estimates?
Ortho Clinical (OCDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
2022-02-18 10:05:27 - Zacks Investment Research
New Strong Buy Stocks for February 18th
CIVI, CLW, OCDX, WCC, and DBI have been added to the Zacks Rank #1 (Strong Buy) List on February 18, 2022.
2022-02-18 10:05:13 - Zacks Investment Research
Best Value Stocks to Buy for February 18th
CIVI, DBI, and OCDX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 18, 2022
2022-02-16 22:28:10 - Seeking Alpha
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Christopher Smith on Q4 2021 Results - Earnings Call Transcript
Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Christopher Smith on Q4 2021 Results - Earnings Call Transcript